Although co-mutations can influence outcomes in AML patients with IDH1 R132 and IDH2 R140Q, these IDH mutations frequently appear alongside NPM1 or DNMT3A, both established indicators of a favorable prognosis. Here, IDH2 is linked to acute myeloid leukemia.